Key Finding
Chronic pain is maintained by maladaptive neuroimmune interactions, with preliminary human imaging and biofluid studies revealing glial activation and suggesting distinct immune endotypes that may guide targeted immunotherapy approaches.
Chronic pain affects millions worldwide and current treatments like opioids often provide limited relief while carrying significant risks. This comprehensive review examines a new understanding of chronic pain: rather than being purely a nerve problem, it may result from ongoing miscommunication between the nervous system and immune system. Researchers analyzed evidence showing that immune cells in the brain (microglia), inflammatory signals (cytokines and chemokines), and failures in the body's natural inflammation-resolution processes all contribute to pain becoming chronic. Advanced imaging techniques (TSPO-PET scans) and cerebrospinal fluid analysis are now providing the first direct evidence of immune activation in people with chronic pain, though patterns vary between different pain conditions. Early clinical trials testing immune-targeted medications—including anti-TNF drugs, CSF-1R inhibitors, and specialized inflammation-resolving compounds—show promise for pain relief, though results are inconsistent and safety concerns remain. For acupuncture patients, this research supports what traditional Chinese medicine has long recognized: that pain involves whole-body imbalance rather than isolated nerve dysfunction. Acupuncture's well-documented anti-inflammatory effects and ability to modulate immune signaling may address these neuroimmune mechanisms directly, offering a safer alternative or complement to pharmaceutical approaches. The review emphasizes precision medicine—matching specific treatments to individual immune profiles—which aligns with acupuncture's individualized, pattern-based approach to pain management. This emerging science validates integrative strategies that address inflammation and immune regulation alongside pain symptoms. To explore acupuncture for chronic pain management, seek a licensed acupuncturist with experience treating pain conditions.
This comprehensive review synthesizes mechanistic and clinical evidence positioning chronic pain as a neuroimmune disorder involving microglial activation, cytokine/chemokine signaling, adaptive immune contributions, and impaired inflammation resolution. Human TSPO-PET imaging studies and cerebrospinal fluid immune profiling provide preliminary in vivo evidence of glial activation, though signals demonstrate heterogeneity suggesting distinct immune endotypes across pain syndromes. Early-phase clinical data from repurposed immunomodulators (anti-TNF agents, CSF-1R inhibitors, specialized pro-resolving mediators) show variable but encouraging effects on pain outcomes, with substantial translational barriers remaining. No sample sizes or effect sizes are provided in this narrative review. The authors propose biomarker-guided stratification and mechanism-aligned endpoints for precision immunotherapy development. Clinical relevance: Acupuncture's demonstrated immunomodulatory effects—including microglial regulation, cytokine modulation, and vagal anti-inflammatory pathway activation—may directly address these neuroimmune mechanisms, supporting its integration into multimodal chronic pain management strategies informed by individual immune profiles.
Browse our directory of verified licensed practitioners near you.
Find a practitioner →📌 Mechanical stimuli may reprogram neuroinflammation and reduce spinal sensitization by modulating microglial and astrocytic reactivity, inflammatory signaling pathways, and neuroimmune synaptic plasticity, providing a mechanistic basis for non-pharmacological pain relief.
📌 Combining electroacupuncture with conventional therapy achieved a 94.55% response rate and 60% reduction in inflammatory markers compared to 78.18% response rate and 32-37% inflammatory reduction with conventional therapy alone in women with chronic pelvic pain.
📌 Pressing intervention alleviates myofascial trigger point pain by downregulating TRPV1 channels in unmyelinated C-type sensory nerve fibers, reducing inflammation and sensory nerve excitability.